- Patient/Guest
- Phlebotomist
- Updates
| CD41a Flow Cytometry Test |
|---|
| Detects CD 41a markers to diagnose platelet disorders, causing excessive bleeding or bruising | ||
 |
Synonym | CD 41a Flow Test |
 |
Test Code | CHEM250029 |
 |
Test Type | Hematology |
 |
Pre-Test Condition | No special |
 |
Report Availability | 1–2 D(s) |
 |
# Test(s) | 1 |
| Test details | Sample Report |
|---|---|
| CD41a Flow Cytometry Test |
|
| Synonym | CD 41a Flow Test | |
| Test Code | CHEM250029 | |
 | Test Category | ||
| Pre-Test Condition | No special | |
 | Medical History | Share & see Updates | |
| Report Availability | 1–2 D(s) | |
 | Specimen/Sample | Refer Updates | |
 | Stability @21-26 deg. C | 24 H(s) | |
 | Stability @ 2-8 deg. C | 48 H(s) | |
 | Stability @ Frozen | Not frozen | |
| # Test(s) | 1 | |
 | Processing Method | Flow Cytometry | |
|
Overview: CD41a Flow Cytometry Test
Introduction: The CD41a Flow Cytometry Test detects CD41a markers to diagnose platelet disorders, causing excessive bleeding or bruising. Following 2023 ASH guidelines, it uses flow cytometry for high specificity, aiding in hematological screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in hematology for patients with suspected platelet disorders. Other Names: CD41a Flow Assay, Integrin Alpha IIb Test. FDA Status: Laboratory-developed test (LDT), meeting hematology standards for diagnostic accuracy. Historical Milestone: CD41a testing began in the 1990s with platelet research. Flow cytometry emerged in the 2000s, improving accuracy for marker detection. Purpose: Diagnoses platelet disorders, guides treatment, and monitors CD41a markers in patients with excessive bleeding or bruising. Test Parameters: 1. CD41a Pretest Condition: No fasting required. Collect whole blood or bone marrow at any time. Report symptoms like bleeding or bruising, and list medications. Specimen: 2-5 mL whole blood (EDTA) or 2-5 mL bone marrow (EDTA). Transport in a biohazard bag within 24 hours. Sample Stability at Room Temperature: 24 hours Sample Stability at Refrigeration: 48 hours Sample Stability at Frozen: Not frozen Medical History: Document bleeding, bruising, or history of platelet disorders (e.g., Glanzmann thrombasthenia). Include current medications, especially anticoagulants. Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for therapy. Procedural Considerations: Uses flow cytometry to detect CD41a markers. Results are available in 1-2 days, enabling rapid clinical decisions. Factors Affecting Result Accuracy: Poor sample quality or low cell yield can affect results. Non-malignant conditions may express CD41a. Clinical Significance: Abnormal CD41a expression suggests platelet disorders, prompting treatment. Normal results may require additional testing. Specialist Consultation: Consult a hematologist for result interpretation. Additional Supporting Tests: Platelet function tests, other flow cytometry markers, or coagulation studies to confirm platelet disorders. Test Limitations: Non-specific expression may occur in non-malignant conditions. Results require clinical correlation. References: ASH Platelet Guidelines, 2023; Blood, George JN, 2022. |